Covid-19: Swissmedic adapts Inspections
Recommendation

14/15 October 2026
Vienna, Austria
Quality Oversight of Pharmaceutical Contract Manufacturing Organisations
Owing to the new situation regarding the COVID-19 pandemic and the differing measures introduced by the various cantons, Swissmedic has decided to adapt the way it carries out inspections. Inspections in the healthcare field will only be performed after prior clarification of possible COVID-19-related capacity problems.
The inspections may be carried out while observing the recommended protective measures - either (partly) by means of remote assessments or at a later point in time. Safety assessments - whether non-routine and scheduled and "for cause", or routine and scheduled but process-specific - will generally take place on site. If inspections are carried out on site, participants must organise the necessary safety precautions for the inspections (meeting rooms with sufficient space, restricted participant numbers, provision of electronic resources such as projectors for document assessment, plus face masks, sanitisers, etc.).
Source: Swissmedic
Related GMP News
07.10.2026FDA: Next Step to Reduce Animal Based Testing Methods
23.09.2026FDA Publishes Draft Guidance on Potency Testing of Active Immunotherapy Products
27.08.2026EMA publishes Consolidated ICH E6(R3) Guideline
28.07.2026WHO publishes GCP Guidelines for Comment
09.07.2026Final ICH E6(R3) Annex 2


